vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Noble Corp plc (NE). Click either name above to swap in a different company.
Noble Corp plc is the larger business by last-quarter revenue ($764.4M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 11.3%, a 7.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -17.6%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $35.4M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 9.5%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Barnes & Noble Booksellers is an American bookseller with the largest number of retail outlets in the United States. The company operates approximately 700+ retail stores across the United States.
MEDP vs NE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $764.4M |
| Net Profit | $135.1M | $86.6M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 5.6% |
| Net Margin | 19.1% | 11.3% |
| Revenue YoY | 32.0% | -17.6% |
| Net Profit YoY | 15.5% | -10.4% |
| EPS (diluted) | $4.65 | $0.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $764.4M | ||
| Q3 25 | $659.9M | $798.0M | ||
| Q2 25 | $603.3M | $848.7M | ||
| Q1 25 | $558.6M | $874.5M | ||
| Q4 24 | $536.6M | $927.3M | ||
| Q3 24 | $533.3M | $800.5M | ||
| Q2 24 | $528.1M | $692.8M | ||
| Q1 24 | $511.0M | $637.1M |
| Q4 25 | $135.1M | $86.6M | ||
| Q3 25 | $111.1M | $-21.1M | ||
| Q2 25 | $90.3M | $42.9M | ||
| Q1 25 | $114.6M | $108.3M | ||
| Q4 24 | $117.0M | $96.6M | ||
| Q3 24 | $96.4M | $61.2M | ||
| Q2 24 | $88.4M | $195.0M | ||
| Q1 24 | $102.6M | $95.5M |
| Q4 25 | 21.6% | 5.6% | ||
| Q3 25 | 21.5% | 6.3% | ||
| Q2 25 | 20.9% | 15.9% | ||
| Q1 25 | 20.3% | 21.4% | ||
| Q4 24 | 23.4% | 18.4% | ||
| Q3 24 | 21.1% | 14.4% | ||
| Q2 24 | 19.9% | 30.3% | ||
| Q1 24 | 20.4% | 16.9% |
| Q4 25 | 19.1% | 11.3% | ||
| Q3 25 | 16.8% | -2.6% | ||
| Q2 25 | 15.0% | 5.1% | ||
| Q1 25 | 20.5% | 12.4% | ||
| Q4 24 | 21.8% | 10.4% | ||
| Q3 24 | 18.1% | 7.6% | ||
| Q2 24 | 16.7% | 28.1% | ||
| Q1 24 | 20.1% | 15.0% |
| Q4 25 | $4.65 | $0.54 | ||
| Q3 25 | $3.86 | $-0.13 | ||
| Q2 25 | $3.10 | $0.27 | ||
| Q1 25 | $3.67 | $0.67 | ||
| Q4 24 | $3.67 | $0.56 | ||
| Q3 24 | $3.01 | $0.40 | ||
| Q2 24 | $2.75 | $1.34 | ||
| Q1 24 | $3.20 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $471.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $4.5B |
| Total Assets | $2.0B | $7.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $471.4M | ||
| Q3 25 | $285.4M | $477.9M | ||
| Q2 25 | $46.3M | $338.2M | ||
| Q1 25 | $441.4M | $303.8M | ||
| Q4 24 | $669.4M | $247.3M | ||
| Q3 24 | $656.9M | $391.9M | ||
| Q2 24 | $510.9M | $162.9M | ||
| Q1 24 | $407.0M | $212.5M |
| Q4 25 | $459.1M | $4.5B | ||
| Q3 25 | $293.6M | $4.5B | ||
| Q2 25 | $172.4M | $4.6B | ||
| Q1 25 | $593.6M | $4.7B | ||
| Q4 24 | $825.5M | $4.7B | ||
| Q3 24 | $881.4M | $4.7B | ||
| Q2 24 | $763.6M | $4.0B | ||
| Q1 24 | $671.5M | $3.9B |
| Q4 25 | $2.0B | $7.5B | ||
| Q3 25 | $1.8B | $7.6B | ||
| Q2 25 | $1.6B | $7.7B | ||
| Q1 25 | $1.9B | $7.9B | ||
| Q4 24 | $2.1B | $8.0B | ||
| Q3 24 | $2.1B | $8.0B | ||
| Q2 24 | $1.9B | $5.6B | ||
| Q1 24 | $1.8B | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $187.1M |
| Free Cash FlowOCF − Capex | $188.1M | $35.4M |
| FCF MarginFCF / Revenue | 26.6% | 4.6% |
| Capex IntensityCapex / Revenue | 0.6% | 19.9% |
| Cash ConversionOCF / Net Profit | 1.43× | 2.16× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $432.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $187.1M | ||
| Q3 25 | $246.2M | $277.1M | ||
| Q2 25 | $148.5M | $216.4M | ||
| Q1 25 | $125.8M | $271.1M | ||
| Q4 24 | $190.7M | $136.2M | ||
| Q3 24 | $149.1M | $283.8M | ||
| Q2 24 | $116.4M | $106.8M | ||
| Q1 24 | $152.7M | $128.7M |
| Q4 25 | $188.1M | $35.4M | ||
| Q3 25 | $235.5M | $139.5M | ||
| Q2 25 | $142.4M | $99.8M | ||
| Q1 25 | $115.8M | $157.5M | ||
| Q4 24 | $183.0M | $-4.4M | ||
| Q3 24 | $138.5M | $156.8M | ||
| Q2 24 | $103.5M | $-34.3M | ||
| Q1 24 | $147.2M | $-37.9M |
| Q4 25 | 26.6% | 4.6% | ||
| Q3 25 | 35.7% | 17.5% | ||
| Q2 25 | 23.6% | 11.8% | ||
| Q1 25 | 20.7% | 18.0% | ||
| Q4 24 | 34.1% | -0.5% | ||
| Q3 24 | 26.0% | 19.6% | ||
| Q2 24 | 19.6% | -4.9% | ||
| Q1 24 | 28.8% | -6.0% |
| Q4 25 | 0.6% | 19.9% | ||
| Q3 25 | 1.6% | 17.3% | ||
| Q2 25 | 1.0% | 13.7% | ||
| Q1 25 | 1.8% | 13.0% | ||
| Q4 24 | 1.4% | 15.2% | ||
| Q3 24 | 2.0% | 15.9% | ||
| Q2 24 | 2.4% | 20.4% | ||
| Q1 24 | 1.1% | 26.2% |
| Q4 25 | 1.43× | 2.16× | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | 5.05× | ||
| Q1 25 | 1.10× | 2.50× | ||
| Q4 24 | 1.63× | 1.41× | ||
| Q3 24 | 1.55× | 4.64× | ||
| Q2 24 | 1.32× | 0.55× | ||
| Q1 24 | 1.49× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
NE
| Floaters | $559.8M | 73% |
| Jackups | $145.5M | 19% |
| Service Other | $59.1M | 8% |
